Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Primary Ovarian Insufficiency Industry In 2025?
The primary ovarian insufficiency market size has experienced strong growth in recent years. It is expected to expand from $1.07 billion in 2024 to $1.18 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.8%. This historical expansion can be attributed to the rising prevalence of autoimmune disorders, increasing stress levels, a greater incidence of genetic mutations, the growing number of women delaying childbirth, and the increasing prevalence of endocrine disorders.
The primary ovarian insufficiency market is projected for significant expansion in the coming years. This market is predicted to reach $1.72 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.9%. This expansion during the forecast period is attributable to the increasing application of assisted reproductive technologies, a rise in the utilization of fertility preservation options, an enhanced focus on personalized medicine, the growing appeal of hormonal therapies, and broader implementation of fertility preservation techniques. Key trends anticipated for the forecast period encompass technological advancements in diagnostics, the incorporation of genetic testing, advancements in fertility preservation technology, novel developments in non-hormonal therapies, and breakthroughs in early detection biomarkers.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24387&type=smp
Which Industry Drivers Are Expected To Accelerate The Primary Ovarian Insufficiency Market From 2025 To 2029?
A rising occurrence of autoimmune conditions is anticipated to fuel the expansion of the primary ovarian insufficiency market in the future. These disorders are characterized by the immune system erroneously targeting and harming the body’s healthy cells and tissues. The surge in autoimmune disorder prevalence is largely attributable to genetic factors, as individuals inherit particular genes increasing their vulnerability to immune system dysfunctions. Primary ovarian insufficiency (POI) provides insights into autoimmune disorders by demonstrating the interplay between hormonal imbalances and immune system dysregulation, which contributes to a higher likelihood of autoimmune diseases in those affected. For example, in November 2024, data from Versorgungsatlas.de, a German organization, showed that in 2022, out of 73,241,305 insured persons, 6,304,340 had been diagnosed with at least one autoimmune disease, representing a raw prevalence rate of 8.61%. Consequently, the growing incidence of autoimmune disorders is a key factor propelling the expansion of the primary ovarian insufficiency market.
What Are The Major Segment Types Covered In The Primary Ovarian Insufficiency Market?
The primary ovarian insufficiencymarket covered in this report is segmented –
1) By Type: Hormone Replacement Therapy (HRT); Calcium and Vitamin D Supplements; In Vitro Fertilization (IVF); Stem Cell Therapy; Other Types
2) By Diagnosis Method: Blood Tests; Ultrasound Imaging; Genetic Testing
3) By Application: Less Than 20 Years Old; 20 To 30 Years Old; 30 To 45 Years Old; 45 Years Old And Older
4) By End-Users: Hospitals And Clinics; Specialty Fertility Centers
Subsegments:
1) By Hormone Replacement Therapy: Estrogen Therapy; Estrogen-Progestin Therapy; Transdermal Patches; Vaginal Estrogen Products; Oral Hormone Therapy
2) By Calcium And Vitamin D Supplements: Calcium Carbonate; Calcium Citrate; Vitamin D2 (Ergocalciferol); Vitamin D3 (Cholecalciferol); Combined Calcium + Vitamin D Formulations
3) By In Vitro Fertilization: Conventional In Vitro Fertilization; Intracytoplasmic Sperm Injection (ICSI); Egg Donation In Vitro Fertilization; Embryo Freezing And Transfer; Preimplantation Genetic Testing (PGT)
4) By Stem Cell Therapy: Autologous Stem Cell Therapy; Allogeneic Stem Cell Therapy; Mesenchymal Stem Cell (MSC) Therapy; Ovarian Stem Cell Transplantation
5) By Other Types: Psychological Counseling And Support Therapies; Assisted Reproductive Technologies (other than IVF); Immunomodulatory Therapies; Lifestyle And Dietary Interventions
Which Key Trends Are Expected To Influence The Primary Ovarian Insufficiency Market In The Coming Years?
Leading companies in the primary ovarian insufficiency market are concentrating on developing innovative treatments, such as allogenic exosomal therapy, with the goal of restoring ovarian function and enhancing fertility outcomes. Allogenic exosomal therapy describes a treatment strategy that employs extracellular vesicles, known as exosomes, sourced from donor stem cells to deliver regenerative signals, thereby promoting tissue repair and reinstating ovarian function in individuals with primary ovarian insufficiency. For instance, in October 2022, Vitti Labs LLC, a US-based biotechnology company, secured approval from the US Food and Drug Administration (FDA), a US-based government agency, for EV-Pure to address primary ovarian insufficiency. This therapy operates by leveraging the regenerative, immunomodulatory, and anti-inflammatory properties of mesenchymal stromal cell-derived exosomes to bring back ovarian function and fertility. EV-Pure provides an off-the-shelf, cell-free treatment that circumvents risks associated with cell-based therapies, such as malignant transformation or immune rejection, while delivering bioactive molecules to encourage tissue repair and homeostasis.
Which Key Market Players Are Investing In Expansion And Innovation Of Primary Ovarian Insufficiency Market?
Major companies operating in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals A/S, The Kingsley Natural Health Clinic, PreventionGenetics LLC, The Fertility Partnership (TFP) UK, Celmatix Inc., European Society of Human Reproduction and Embryology (ESHRE), Endocrine Society, IVIRMA Global, American Society for Reproductive Medicine (ASRM), TCM Healthcare (UK) Ltd., Bioscience Institute S.p.A., Sparsh Diagnostics Pvt. Ltd., Welling Homeopathy Clinics Pvt. Ltd., Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty. Ltd., OvaScience Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/primary-ovarian-insufficiency-global-market-report
How Does The Primary Ovarian Insufficiency Market Perform Across Key Geographic Regions?
North America was the largest region in the primary ovarian insufficiency market in 2024. The regions covered in the primary ovarian insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Primary Ovarian Insufficiency Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24387&type=smp
Browse Through More Reports Similar to the Global Primary Ovarian Insufficiency Market 2025, By The Business Research Company
Ovarian Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2025
Ovarian Cancer Drugs Market 2025
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model